Table 1.
Baseline Characteristics Between Treatment Groups
| Characteristic | Study Group | |
|---|---|---|
| Placebo (n = 121) | Voriconazole (n = 119) | |
| Sex, No. (%) | ||
| Male | 71 (58.7) | 65 (54.6) |
| Female | 50 (40.3) | 54 (45.4) |
| Age, median (IQR), y | 50 (45–60) | 54 (42–62) |
| Weight, median (IQR), kg | 49 (44–55) | 48 (43–56) |
| Occupation, No. (%) | ||
| Agriculture | 69 (57) | 72 (60.5) |
| Nonagriculturea | 52 (43) | 47 (39.5) |
| Medication use at enrollment, No. (%) | ||
| Topical ocular antifungals | 90 (74.4) | 81 (68.1) |
| Other topical ocular eyedrops | 26 (21.5) | 30 (25.2) |
| Systemic antifungals | 10 (8.3) | 9(7.6) |
| Other systemic agents | 19 (15.7) | 25 (21) |
| Trauma or injury, No. (%)b | ||
| Vegetative matter or wood | 44 (36.4) | 30 (25.2) |
| Metal or otherc | 29 (24) | 34 (28.6) |
| Unknown object | 4(3.3) | 2(1.7) |
| None | 43 (35.5) | 51 (42.9) |
| Affected eye, No. (%)b | ||
| Right | 67 (55.4) | 72 (60.5) |
| Left | 53 (43.8) | 46 (38.7) |
| Visual acuity, median (IQR) | ||
| LogMAR | 1.7 (1.2–1.8) | 1.7 (1.5–1.8) |
| Snellen | CF (20/400, HM) | CF (20/630, HM) |
| Infiltrate and/or scar, median (IQR), mmc | 5.3 (4.6–6.5) | 5.5 (4.4–6.9) |
| Hypopyonb | ||
| No | 33 (27.3) | 32 (26.9) |
| <0.5 mm | 20 (16.5) | 19 (16) |
| ≥0.5 mm | 64 (52.9) | 66 (55.5) |
| Depth, %b | ||
| >0–33 | 35 (28.9) | 24 (20.2) |
| >33–67 | 51 (42.1) | 51 (42.9) |
| >67–100 | 33 (27.3) | 44 (37) |
| Epithelial defect, median (IQR), mmd | 4.7 (3.7–5.9) | 4.6 (3.3–5.8) |
| Duration of symptoms, median (IQR), d | 10 (7–16) | 10 (7–15) |
| Systemic disease, No. (%)e | 11 (9.1) | 15 (12.6) |
Abbreviations: CF, counting fingers; HM, hand motions; IQR, interquartile range.
a
Includes unemployed or retired.
b
Some data missing.
c
Includes dust, battery acid, ash, cement, fingernail, stick, cow or buffalo tail, goat horn, and insect.
d
Geometric mean of the longest diameter and longest perpendicular to that diameter in millimeters.
e
Includes diabetes, asthma, and hypertension.